Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 12/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811822 | 0.83 | ACHE (0.36) | ACHECD274TSHRBACE1CYP3A4 | |
| SCHEMBL20820440 | 0.83 | ACHE (0.38) | ACHECD274LMNAGAAMAPT | |
| SCHEMBL16371989 | 0.80 | CA12 (0.47) | LMNAMAPTTSHRMAPK1 | |
| SCHEMBL26326796 | 0.79 | NPC1 (0.47) | ACHEMAPTTDP1L3MBTL1BACE1 | |
| SCHEMBL28320048 | 0.78 | ACHE (0.36) | ACHECD274BACE1 | |
| SCHEMBL22965291 | 0.77 | KMT2A (0.45) | ACHELPAR1LMNABACE1 | |
| SCHEMBL17815741 | 0.75 | ACHE (0.49) | ACHEGAAMAPTMAPK1TDP1 | |
| SCHEMBL14258683 | 0.73 | ACHE (0.52) | ACHELPAR1EPHX1LMNAGAA | |
| SCHEMBL17815748 | 0.72 | ACHE (0.38) | ACHECD274GAAMAPTMAPK1 | |
| SCHEMBL13159618 | 0.70 | ACHE (0.48) | ACHELPAR1EPHX1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | ACHE 268/4885CD274 4548/4885LPAR1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.